U.S. Markets closed

Plandaí Biotechnology, Inc. (PLPL)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.015+0.001 (+11.111%)
At close: 3:37PM EDT
People also watch
EDXCNTRRATTBFFSPMFITX

Plandaí Biotechnology, Inc.

17 Hanover Square
London W1S 1BN
United Kingdom
44 91 7900 9829
http://www.plandaibiotech.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees250

Key Executives

NameTitlePayExercisedAge
Mr. Roger Baylis-DuffieldCo-Founder, Chairman and Chief Exec. Officer180kN/A74
Mr. Callum Baylis-DuffieldPres, Chief Operating Officer and Director120kN/A32
Ms. Daron Baylis DuffieldCo-Founder and Director45kN/A66
Mr. Ezra JonesVP of Sales and MarketingN/AN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Plandaí Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, Artemisia, and cannabis. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. Plandaí Biotechnology, Inc. is based in London, the United Kingdom.

Corporate Governance

Plandaí Biotechnology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.